Stem Cell Bioprocessing

TODAY’S RESEARCH, TOMMOROW’S CELLULAR THERAPY

In the Stem Cell Bioprocessing group, we focus on the scalable production of stem cells and their derivatives at sufficient quality and quantity for cell and gene therapy. Furthermore, we have the expertise to screen and test biomaterials for stem cell expansion, maturation and formation of tissue-engineered models for regenerative medicine, drug screening and cultured meat applications.

Focus Areas

Process development for scalable human pluripotent and mesenchymal stem cell manufacturing
Reprogramming of human induced pluripotent stem cells on microcarriers
CRISPR activation-mediated cell differentiation
Media development for stem cell cultures

Microcarriers

Accelerated reprogramming
Robust
Scalable
High yield

Stem Cell Media Formulation

Serum-free
Xeno-free

Stem Cell Differentiation

CRISPR activation-mediated
Microcarrier-based
High yield

All-In-One Platform for Reprogramming on Microcarriers (RepMC)

Speed: Accelerate reprogramming by 7 days faster than monolayer
Robust: Ability to expand and efficiently differentiate to the three germ-layers, heart cells and blood cells
Various Cell Sources: fibroblasts, peripheral blood mononuclear cells, T cells and CD34+ blood stem cells
Automation Ready: Platform is also amenable to automation for processing more donor samples in a small footprint, allowing robotic processes to replace manual handling

Microcarrier-based Bioreactor System

Robust: tested and proven in human pluripotent and mesenchymal stem cell expansion
Scalable: up to 5L while maintaining pluripotency of stem cells
High yield: 3 to 10-fold higher than conventional 2D cultures

Featured Publications

Alan Tin Lun Lam, Valerie Ho, Svetlan Vassilev, Shaul Reuveny and Steve Kah Weng Oh (2022) An allied reprogramming, selection, expansion and differentiation platform for creating hiPSC on microcarriers. Cell Proliferation 55:e13256
Alan Tin-Lun Lam, Alison P. Lee, Premkumar Jayaraman, Kah Yong Tan, Deepak Raghothaman, Hsueh Lee Lim, He Cheng, Lihan Zhou, Andy Hee-Meng Tan, Shaul Reuveny and Steve Oh (2021) Multiomics analyses of cytokines, gene, miRNA, and pathway regulatory networks in human mesenchymal stem cells expanded in stirred microcarrier-spinner cultures. Stem Cell Research 53:102272
Jaichandran Sivalingam, Yu SuE, Zhong Ri Lim, Alan T.L. Lam, Alison P. Lee, Hsueh Lee Lim, Hong Yu Chen, Hong Kee Tan, Tushar Warrier, Jing Wen Hang, Nazmi B. Nazir, Andy H.M. Tan, Laurent Renia, Yuin Han Loh, Shaul Reuveny, Benoit Malleret and Steve K.W. Oh (2020) A Scalable Suspension Platform for Generating High-Density Cultures of Universal Red Blood Cells from Human Induced Pluripotent Stem Cells. Stem Cell Reports 16(1): 182-197
Alan Tin-Lun Lam, Allen Kuan-Liang Chen, Sherwin Qi-Peng Ting, Shaul Reuveny and Steve Kah-Weng Oh (2016) Integrated processes for expansion and differentiation of human pluripotent stem cells in suspended microcarriers cultures. Biochemical and Biophysical Research Communications 473(3): 764-8

Featured Publications

Microcarriers for stem cell culture (2014)
Culture of pluripotent and multipotent cells on microcarriers (2014)

Dr Alan Lam

alan_lam@bti.a-star.edu.sg
Senior Scientist II

PhD in Biochemistry (2003), The Chinese University of Hong Kong, Hong Kong

Research Focus / Interest

Scalable production of human embryonic stem cells, human induced pluripotent stem cells and human mesenchymal stem cells and its differentiated cells
Medium development for large-scale expansion of mesenchymal stem cells in bioreactors

Dr Leonard Leong

leonard_leong@bti.a-star.edu.sg
Scientist

PhD in Immunology (2021), NUS Graduate School (Integrative Sciences and Engineering Programme), National University of Singapore, Singapore

Research Focus / Interest

Development of novel chimeric antigen receptors for adoptive immunotherapy
Scalable production and differentiation of induced pluripotent stem cells into immune cell subsets
Development of allogeneic cell therapeutics for anti-cancer applications

��